News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase III
Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3/30/2015
Synageva BioPharma (GEVA) Submits Kanuma (Sebelipase Alfa) Application For LAL Deficiency In Mexico 3/30/2015
Teva (TEVA) Reinforces Leadership Position In CNS With Acquisition Of Auspex Pharmaceuticals (ASPX) 3/30/2015
BioDelivery Sciences International (BDSI) Clonidine Topical Gel Fails Phase III, Shares Plunge 3/30/2015
Adamis (ADMP) Plummets More Than 30% After FDA Rejects Its Allergy Shot Application 3/30/2015
Cardio3 BioSciences Successfully Completes Futility Analysis Of Lead Cardiac Cell Therapy, C-Cure 3/30/2015
Can-Fite BioPharma (CFBI) Reports Top-Line Results From Phase II/III Trial For CF101 In Treatment Of Psoriasis 3/30/2015
Morphotek Inc. Announces Initiation Of Farletuzumab Study In Patients With First-Relapsed, Platinum-Sensitive Ovarian Cancer With Low Levels Of The Immunosuppressive CA125 Tumor Antigen 3/30/2015
Janssen Research & Development Release: New Study Published In JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time To Relapse In Patients With Schizophrenia 3/30/2015
Alnylam (ALNY) Initiates ENDEAVOUR Phase 3 Clinical Trial With Revusiran 3/27/2015
European Medicines Agency Release: Accelerated Assessment Fast-Tracks Lenvima To Benefit Patients With Thyroid Cancer 3/27/2015
GENFIT (ALGFT)'s GFT505 Misses Target in Phase IIB But Hopes to Proceed to Phase III 3/27/2015
NephroGenex (NRX) Announces Data On Acute Kidney Injury At National Kidney Foundation 2015 Spring Clinical Meetings 3/27/2015
Northwest Biotherapeutics (NWBO) Reports Promising Survival Data In 51 Gbm Patients Treated With Dcvax-L 3/27/2015
Galderma Announces Positive Outcome Of European Decentralised Procedure For Approval Of Soolantra (Ivermectin) Cream 10mg/G For Rosacea Patients 3/27/2015
Results Of Auspex Pharmaceuticals (ASPX)' Phase 3 Registration Trial Of SD-809 To Be Presented At American Academy of Neurology Annual Meeting 3/27/2015
Relypsa (RLYP) Presents Sub-Group Analysis From Phase 3 Study Of Patiromer FOS In Patients With Advanced Chronic Kidney Disease At 2015 National Kidney Foundation Spring Clinical Meeting 3/27/2015
Merck & Co. (MRK) Study Halted on Positive Phase III Data 3/26/2015
pSivida Corp (PSDV) Completes Targeted Enrollment Of Phase III Trial Of Medidur For Posterior Uveitis 3/26/2015
Novavax, Inc. (NVAX) Prices Public Offering Of Common Stock 3/26/2015
Cardio3 BioSciences Reports 2014 Financial And Operating Results 3/26/2015
Neothetics Reports Fourth Quarter and Full Year 2014 Financial Results 3/26/2015
Onxeo Expands Livatag International Phase III Clinical Trial "Relive" To 3 New Countries 3/26/2015
Lexicon Pharmaceuticals, Inc. (LXRX) Announces First Patient Screened In Pivotal Phase 3 Clinical Trial Of Sotagliflozin 3/25/2015
Vericel (ASTM) Reports Three-Year Follow-Up Results From Phase 3 SUMMIT Extension Study Of MACI Implant 3/25/2015
TRANSGENE (ENX:TNG) Reports 2014 Financial Results And Outlines Promising Clinical Pipeline 3/25/2015
NephroGenex (NRX) Reports Financial Results For The Fourth Quarter And Year Ended December 31, 2014 3/25/2015
RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives Initial Payment For RGN-259 U.S. License To ReGenTree Joint Venture 3/25/2015
ThromboGenics NV (TBGNF) Announces Positive Topline Results From OASIS Study 3/24/2015
Mast Therapeutics (MSTX) Reports Fourth Quarter And Full Year 2014 Financial Results 3/24/2015
Aerie Pharmaceuticals, Inc. (AERI) Completes Enrollment In Second Phase 3 Registration Trial (“Rocket 2”) Of Rhopressa, Novel Triple-Action Product To Lower Intraocular Pressure In Patients With Glaucoma 3/24/2015
La Jolla Pharmaceutical Company (LJPC) Announces Initiation Of Phase III Clinical Trial Of LJPC-501 In Catecholamine-Resistant Hypotension 3/24/2015
LFB S.A. Receives Go Ahead From Data Monitoring Committee To Expand The Global PERSEPT Phase 3 Program Of LR769 In Hemophilia A Or B Patients With Inhibitors 3/24/2015
Can-Fite BioPharma (CFBI) Signs Multi-Million Dollar Distribution Agreement For CF101 In Canada With Cipher Pharmaceuticals (DND.TO) 3/23/2015
Cipher Pharmaceuticals (DND.TO) Acquires Canadian Rights To Novel Treatment For Psoriasis And Rheumatoid Arthritis 3/23/2015
Novartis AG (NVS) Presents Cosentyx Two-Year Efficacy And Safety Data Showing Sustainable Effect In Psoriasis Patients 3/23/2015
EXCLUSIVE: Resverlogix Corporation (RVX.TO) CEO Says Experimental Cardiac Drug Holds High Hopes, As Biotech Booms 3/20/2015
AbbVie (ABBV) Elated as Pharmacyclics (PCYC)'s Imbruvica Shines in Combo Trial 3/20/2015
Nektar Therapeutics (NKTR) Cancer Drug Improves Survival But Misses Primary Endpoint, As Watchers Worry 3/20/2015
Intarcia Therapeutics, Inc. And Numab AG Sign Multi-Asset Collaboration To Develop Once-Yearly Therapies In Diabetes, Obesity, and Autoimmune Indications 3/20/2015
Anthera, Inc. Announces $3 Million Research Award From Cystic Fibrosis Foundation Therapeutics, Inc. For Development Of Sollpura - A Novel Enzyme Therapy 3/20/2015
Amgen (AMGN) Submits Application For Investigational LDL Cholesterol-Lowering Medication Repatha (evolocumab) In Japan 3/20/2015
ImmunoCellular Therapeutics, Ltd (IMUC) Chooses PharmaCell As Contract Manufacturing Partner For Its Phase III Program In Europe 3/20/2015
Galderma Laboratories Announces Positive Phase 3 Trial Results Of Investigational Adapalene 0.3%/Benzoyl Peroxide 2.5% (0.3% A/BPO) For The Treatment Of Acne 3/20/2015
New Novartis AG (NVS) Data Show More Cosentyx-Treated Psoriasis Patients Achieved Clear Or Almost Clear Skin (PASI 90) Compared To Stelara 3/20/2015
Celgene (CELG) Release: Oral Otezla (Apremilast) Long-Term Safety And Efficacy Data In Patients With Moderate To Severe Plaque Psoriasis Presented At American Academy of Dermatology 3/20/2015
Celgene (CELG) Release: Positive Results From Phase III Study Evaluating Oral Otezla (Apremilast) Or Injectable Etanercept Versus Placebo In Patients With Moderate To Severe Plaque Psoriasis Presented At American Academy of Dermatology 3/20/2015
Sanofi (SAN.PA) Test Shows Lixisenatide Doesn't Up Cardiovascular Risk 3/19/2015
ImmunoCellular Therapeutics, Ltd (IMUC) Establishes Manufacturing Agreement With Pharmacell B.V. For European Production Of ICT-107 For Phase 3 Registration Trial 3/19/2015
PTC Therapeutics (PTCT) And University of Pennsylvania Collaborate On Orphan Disease Research 3/19/2015
ZS Pharma (ZSPH) To Present Data From Phase 3 Trials Of ZS-9 In Presentations At The National Kidney Foundation 2015 Spring Clinical Meetings 3/19/2015
Scioderm Initiates Phase 3 Registration Trial Of Zorblisatm (SD-101), A Novel Topical Therapy For Patients With Epidermolysis Bullosa 3/19/2015
AstraZeneca PLC (AZN) Two-in-One Lung Drug Succeeds in Phase III Trial 3/19/2015
New Cholesterol Drugs From Amgen (AMGN), Sanofi (SAN.PA), Regeneron (REGN) Cut Heart Risks in Half But Questions Remain 3/18/2015
AstraZeneca PLC (AZN) Announces Positive Phase III Top-Line Results For PT003 From PINNACLE 1 And PINNACLE 2 Studies In COPD 3/18/2015
Lexicon Pharmaceuticals, Inc. (LXRX) And Ipsen (IPN.PA) Expand Their Licensing And Commercialization Agreement For Telotristat Etiprate To Include Canada 3/18/2015
Tenax Therapeutics (TENX) Announces Third Quarter Fiscal Year 2015 Financial Results 3/18/2015
Biogen Idec (BIIB) Will Be Hiring in R&D After Around 20 Employees Leave Following Review 3/17/2015
Pharmacyclics (PCYC) Release: Independent Data Monitoring Committee Unanimously Recommends Unblinding Of IMBRUVICA (Ibrutinib) Phase III Combination HELIOS Trial Based On Interim Analysis Showing Significant Improvement In Progression-Free Survival In Patients With Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma 3/17/2015
Sinovac Biotech Ltd. (SVA) Provides Updates On Pipeline Vaccines 3/17/2015
Collegium To Present Xtampza ER Pivotal Phase III Data At The 2015 American Academy Of Pain Medicine Annual Meeting 3/17/2015
The Lancet Publishes CSL Behring's Kcentra Phase III Data 3/17/2015
QIAGEN N.V. (QGEN) Expands Leadership In Liquid Biopsies With New Circulating Tumor Cell Technology For Development Of Companion Diagnostics 3/17/2015
Anavex (AVXL) To Participate In Phase 3 Clinical Trials Panel At AD/PD 2015 3/17/2015
Sanofi (SAN.PA), Regeneron (REGN): 18-Month Results Of ODYSSEY LONG TERM Trial With Praluent (Alirocumab) Published In The New England Journal of Medicine 3/16/2015
Amgen (AMGN) Release: New Detailed Data From Phase 3 Study Show Amgen's Repatha (Evolocumab) In Combination With Statins Reduced LDL-C By 67-76 Percent Compared To Placebo In Japanese Patients With High Cardiovascular Risk And High Cholesterol 3/16/2015
Amgen (AMGN) Publishes Safety Analysis Of Investigational Cholesterol-Lowering Medication Repatha (evolocumab) In The The New England Journal of Medicine 3/16/2015
AcelRx (ACRX) Announces Initiation Of Pivotal Phase 3 Trial For ARX-04 3/16/2015
Anthera Pharmaceuticals, Inc. (ANTH) Announces Completion Of Interim Analysis From Phase 3 Trial With Blisibimod For IgA Nephropathy 3/16/2015
Yisheng Biopharma Co., Ltd. Release: A New Therapeutic Vaccine Successfully Developed Against Rabies 3/16/2015
Provectus Biopharmaceuticals Inc.’ Amended Protocol Of PV-10 For Phase III Study As Treatment For Melanoma Now Available Online 3/16/2015
Mezzion Pharma Commits To Phase 3 Clinical Trials Of Udenafil In Adolescents With A Single Functional Ventricle That Have Undergone Fontan Surgical Palliation 3/16/2015
Medivir AB (MVRBF): New Data On Simeprevir Presented At The Conference Of The Asian Pacific Association For The Study Of The Liver 3/16/2015
Baxter BioScience Corporation (BAX) Announces Positive Phase III Results For BAX 817, Investigational Recombinant Treatment For Hemophila A And B Patients With Inhibitors 3/13/2015
Cytokinetics, Inc. (CYTK) Announces Completion Of Enrollment In COSMIC-HF 3/13/2015
Charleston Laboratories, Inc. And Daiichi Sankyo (4568.t) Announce Completion Of A Pharmacokinetics Study On CL-108 3/12/2015
Provectus Biopharmaceuticals Inc. Updates Market On Business Developments 3/12/2015
Cynapsus Therapeutics (CYNAF) Provides Clinical And Regulatory Update For APL-130277 For The Acute Rescue Of OFF Motor Symptoms Of Parkinson’s Disease 3/12/2015
XBiotech Launches Website And Call Center To Inform Cancer Patients About New Xilonix Therapy And Phase III Clinical Study 3/12/2015
At a Top Notch Facility in SoCal, Amgen (AMGN) Works on Perfecting and Cranking Out Biosimilars 3/11/2015
PharmaEssentia And AOP Orphan Announce Completion Of Recruitment Of Pivotal Phase III Trial PROUD-PV 3/11/2015
Dr. Anita J. Chawla Joins CytRx Corporation (CYTR) Board Of Directors To Add Additional Drug Commercialization Expertise In Oncology 3/11/2015
Takeda (TKPYY) Announces Publication In The Lancet Of A Post Hoc Analysis Of Data From The EXAMINE Cardiovascular Safety Outcomes Trial 3/10/2015
Auris Medical AG (EARS) Announces Completion Of Interim Analysis In Post-Acute Tinnitus Stratum Of TACTT3 Trial With AM-101 3/10/2015
Ocular Therapeutix, Inc. (OCUL) Reports Positive Topline Clinical Data For The First Of Two Phase 3 Clinical Trials Evaluating OTX-DP For The Treatment Of Post-Surgical Ocular Inflammation And Pain 3/10/2015
Lexicon Pharmaceuticals, Inc. (LXRX) Completes Enrollment In Pivotal Phase 3 Clinical Trial Of Telotristat Etiprate 3/9/2015
Novo Nordisk A/S (NVO) Release: New Data In Adults With Obesity Or Who Are Overweight With Comorbidities Losing At Least 5% Body Weight With Saxenda (liraglutide [rDNA origin] injection) Showed Improvement In Blood Glucose, CV Risk Factors And Quality Of Life Outcomes 3/9/2015
ContraVir Pharmaceuticals To Initiate Pivotal Phase 3 Study Of FV-100 For Prevention Of Shingles-Associated PHN 3/9/2015
CTI BioPharma, Baxter International (BAX)'s Blood Cancer Drug Meets Main Goal in Late-Stage Trial 3/9/2015
Opexa Therapeutics (OPXA) Amends Agreement With Merck Serono And Receives Additional $3 Million Payment To Support Ongoing Development Of Tcelna For Multiple Sclerosis 3/9/2015
R-Tech Ueno: The End Of A Phase 3 Clinical Study And Preliminary Findings From A Phase 3 Of Unoprostone (Development Code UF-021) For Treatment Of Retinitis Pigmentosa 3/9/2015
Trimel Pharmaceuticals (TRL.TO) Announces Natesto Abstract Presentation At The 2015 Endocrine Society Annual Meeting 3/9/2015
EXCLUSIVE: Experimental Cancer Drug From Oncoceutics Could Be Fast-Tracked, Says Exec 3/6/2015
Orexigen (OREX)'s Failure to Keep a Lid on it Prompts the FDA to Force a Second Study 3/6/2015
BioLineRx Ltd. Announces Underwritten Public Offering Of Its American Depositary Shares 3/6/2015
AEterna Zentaris (AEZS) Announces Pricing Of US$37 Million Public Offering Of Common Shares And Warrants 3/6/2015
CytoTools: European Trials On Diabetic Foot And Ulcus Cruris (Leg Ulcers) On Schedule - Delay In The Market Approval For The Wound Healing Agent Dermapro In India 3/6/2015
Catalyst Pharmaceuticals (CPRX) Announces FDA Orphan Drug Designation Of Firdapse For Treatment Of Congenital Myasthenic Syndromes 3/5/2015
AOP Orphan Pharmaceuticals AG Announces Progress Of Pivotal Phase 3 Trial PROUD-PV Applying Ropeginterferon ALFA 2B, A Novel, Long-Acting, Mono-Pegylated Interferon For Treatment Of Polycythemia Vera 3/5/2015
Chiasma Announces New Data For Investigational Octreotide Capsules 3/5/2015
Lexicon Pharmaceuticals, Inc. (LXRX) Provides Clinical Pipeline Update And Reports 2014 Fourth Quarter And Full Year Financial Results 3/4/2015
Keryx Biopharmaceuticals (KERX) Announces Publication Of Auryxia (Ferric Citrate) Analysis In Journal Of The American Society Of Nephrology 3/4/2015
CorMedix (CRMD) Provides Multiple Strategic Business Updates 3/4/2015
Drug Approved In Pivotal Studies Using DSG, Inc.’s Fully Electronic Source Data 3/3/2015
Delcath Systems, Inc. (DCTH) Announces Submission Of Phase 3 Trial Results For Publication In A Leading Peer-Reviewed Medical Journal 3/3/2015
Amgen (AMGN) Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 3/3/2015
CEL-SCI (CVM) Reports 2nd Consecutive Month Of Record Patient Enrollment In 2015 For Its Phase III Head And Neck Cancer Trial 3/3/2015
Gilead (GILD)'s Harvoni Achieves 96% Cure Rate in Patients With Hepatitis C and HIV 3/2/2015
Otsuka Pharmaceutical Co., Ltd. Release: First-Ever Treatment Approved In Canada For Adults Living With ADPKD, A Life-Threatening Kidney Disease 3/2/2015
Portola Pharmaceuticals, Inc. Announces Full Results From Positive Phase 3 ANNEXA-R Study Demonstrating That Andexanet Alfa Rapidly And Significantly Reversed Anticoagulant Effect Of Factor Xa Inhibitor XARELTO 3/2/2015
Dynavax Technologies Corporation (DVAX) Announces Second Independent DSMB Recommendation To Continue Phase 3 Study Of HEPLISAV-B 3/2/2015
Amgen (AMGN) Release: Phase 3 Head-To-Head ENDEAVOR Study Demonstrates Superiority Of Kyprolis (Carfilzomib) Over Velcade (Bortezomib) In Patients With Relapsed Multiple Myeloma 3/2/2015
CEL-SCI (CVM) Completes Key Milestone With Clearance To Conduct Phase 3 Trial In 21 Countries 3/2/2015
Isis Pharmaceuticals, Inc. (ISIS) Earns $15 Million From GlaxoSmithKline (GSK) for Advancing ISIS-TTR Rx 3/2/2015
Amgen (AMGN)'s Hormone-Imbalance Drug AMG 416 Shows Positive Results in Phase 3 Study 2/27/2015
Gilead (GILD) Announces SVR12 Rates From Phase III Study Evaluating Harvoni For The Treatment Of Chronic Hepatitis C In Patients Co-Infected With HIV 2/27/2015
Argos Therapeutics, Inc. (ARGS) Announces Update On Phase 3 ADAPT Trial To Be Presented During 2015 ASCO Genitourinary Cancers Symposium 2/27/2015
Amgen (AMGN) Receives Positive CHMP Opinion For Use Of Vectibix (panitumumab) As First-Line Treatment In Combination With FOLFIRI Chemotherapy For Advanced Colorectal Cancer 2/27/2015
Biogen Idec (BIIB) And Swedish Orphan Biovitrum Announce Positive Top-Line Efficacy And Safety Results From Phase 3 ALPROLIX Pediatric Study 2/27/2015
Gilead (GILD) Announces Phase 3 Results For Investigational Once-Daily Single Tablet HIV Regimen Containing Tenofovir Alafenamide (TAF) 2/27/2015
Bristol-Myers Squibb (BMY) Release: ALLY Trial Demonstrates 97% Hepatitis C Cure Rates Among Patients Coinfected With HIV After Ribavirin-Free Investigational 12-Week Regimen Of Daclatasvir And Sofosbuvir 2/27/2015
TherapeuticsMD, Inc.  (TXMD) Has "Multiple Catalysts" in 2015/16 As Products Develop, Says Cowen and Company 2/26/2015
ABIVAX Recruits First Patient In A Pivotal Phase 2b/3 Clinical Trial With ABX203, A Novel Immunotherapy Against Chronic Hepatitis B 2/26/2015
Chimerix (CMRX) Provides Update On Anticipated SUPPRESS Enrollment 2/26/2015
Portola Pharmaceuticals, Inc. Receives FDA Orphan Drug Designation For Andexanet Alfa, Its Breakthrough-Designated Factor Xa Inhibitor Antidote 2/26/2015
Gradalis Inc. Announces Initiation Of A Phase 3 Registration Study For Vigil In Ovarian Cancer 2/26/2015
Bristol-Myers Squibb (BMY) Release: Study Of Next-Generation Investigational HIV-1 Maturation Inhibitor Shows Positive Results In Preventing Viral Replication Via Different Mechanism Of Action Than Current Therapies 2/26/2015
Amgen (AMGN) Announces Positive Results From Head-To-Head Study Comparing The Efficacy And Safety Of AMG 416 With Cinacalcet In Patients With Secondary Hyperparathyroidism Receiving Hemodialysis 2/26/2015
Eisai Inc. (ESALF.PK) Release: Topline Results Of Phase 3 Trial Show Eribulin Mesylate Injection Meets Primary Endpoint Of Overall Survival In Advanced Soft Tissue Sarcoma 2/25/2015
Dipexium Pharmaceuticals (DPRX) Passes 25% Enrollment In Locilex Pivotal Phase 3 Clinical Trials 2/25/2015
Nektar Therapeutics (CA) (NKTR) Announces Start Of Phase 3 SUMMIT-07 Study Of NKTR-181 In Patients With Chronic Low Back Pain 2/25/2015
Sunovion Pharmaceuticals Inc. Announces Initiation Of Phase 3 Clinical Trial Program For SUN-101/Eflow (Glycopyrrolate) In Moderate-To-Very Severe Chronic Obstructive Pulmonary Disease (COPD) 2/25/2015
Bristol-Myers Squibb (BMY) Release: 48-Week Analysis Of Investigational HIV-1 Attachment Inhibitor Paves Way For Phase III Trial Initiation 2/25/2015
Antares Pharma, Inc. (ATRS) Announces Positive Top-Line Pharmacokinetic Results From The Quickshot Phase 3 Study In Testosterone Deficient Men 2/25/2015
Cytori Therapeutics, Inc. (CYTX) Receives Positive European Opinion On Orphan Drug Status 2/24/2015
Theravance Biopharma Enrolls First Patient In Phase 3 Registrational Study Of Telavancin In Staphylococcus Aureus Bacteremia 2/24/2015
Teva Pharmaceutical Industries (TEVA) Release: The Lancet Respiratory Medicine And AAAAI Publish Positive Data From Phase 3 Trials Of Teva’s Reslizumab For The Treatment Of Moderate To Severe Asthma In Patients With Elevated Blood Eosinophils 2/24/2015
Celsion Corporation (CLSN) Announces Updated Overall Survival Data from HEAT Study of ThermoDox In Primary Liver Cancer 2/23/2015
TiGenix's Phase III Trial Design For Cx601 Endorsed By President-Elect Of ECCO 2/23/2015
ADMA Biologics, Inc. Announces Positive Data On Primary And Secondary Endpoints From Its Pivotal Phase III Clinical Trial For RI-002 At The American Academy of Allergy, Asthma and Immunology (AAAAI) Medical Conference 2/23/2015
Hemispherx Biopharma (HEB): Institute Of Medicine, The Health Arm Of The US National Academy of Sciences Reframes Chronic Fatigue Syndrome (CFS) As A "Systemic Exertion Intolerance Disease" (SEID) 2/23/2015
Eli Lilly (LLY) Release: Baricitinib Superior To Placebo In Reducing Rheumatoid Arthritis Disease Activity In Second Phase 3 Study 2/23/2015
Results from AbbVie (ABBV)'s Study Of VIEKIRA PAK (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) In Chronic Hepatitis C Patients With HIV-1 Co-Infection (TURQUOISE-I) Published Online In JAMA; Sub-Analyses To Be Presented At The Annual Conference On Retroviruses And Opportunistic Infections (CROI) 2/23/2015
BioTie Therapies Corp. Provides Portfolio Update On Tozadenant 2/20/2015
Pierre Fabre Release: A phase 2/3 Clinical Data Published In The NEJM Confirms Positive Safety-Efficacy Profile For First Pediatric Treatment For Infantile Hemangioma 2/20/2015
Immunomedics, Inc. (IMMU) Presents Updated Results With Sacituzumab Govitecan in Lung Cancer 2/20/2015
Actavis (ACT) Touts Potential $6 Billion Pipeline at Investor Meeting 2/19/2015
EXCLUSIVE: Chimerix (CMRX) Says 2015 Will Be "Pivotal" Year, In Talks With Regulators to Use Antiviral After Transplants 2/19/2015
Takeda (TKPYY) Lung Cancer Drug Motesanib Flunks Late Stage Trial 2/19/2015
Nuo Therapeutics Initiates Phase 4 Study Of Aurix Under CMS Coverage With Evidence Development Program 2/19/2015
Eli Lilly (LLY) Provides Update On Evacetrapib Phase 3 Trial 2/19/2015
CEL-SCI (CVM)’s Phase III Head And Neck Cancer Trial Cleared To Begin Patient Enrollment In Malaysia, The 20th Country To Join The Trial 2/19/2015
Sanofi (SAN.PA)'s Cerdelga Shows Promise in Late Stage Trial 2/18/2015
Genzyme (GENZ) Release: ENGAGE Randomized Clinical Trial Evaluating Cerdelga® (Eliglustat) For Treatment-Naïve Patients With Gaucher Disease Type 1 Published In JAMA 2/18/2015
Elite Pharmaceuticals, Inc. (ELI) Provides Guidance On Phase III Study For ELI-200 2/18/2015
PAREXEL International (PRXL) Simplifies Patient Recruitment And Study Start-Up Timelines Through Innovative Site Alliance Network 2/18/2015
Seattle Genetics, Inc. (SGEN) Submits Supplemental BLA To FDA For Phase 3 AETHERA Trial Of ADCETRIS® (Brentuximab Vedotin) In Post-Transplant Hodgkin Lymphoma Patients At High Risk Of Relapse 2/18/2015
Takeda (TKPYY) Announces Phase 3 MONET-A Study Evaluating Motesanib (AMG 706) In Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Does Not Meet Primary Endpoin 2/17/2015
Hyperion Therapeutics (HPTX) Enters Into Completion Of Phase III Clinical Trial, Option And Mutual Release Agreement With Clal Biotechnology Industries And Yeda Research and Development Company Ltd. 2/17/2015
MediVector Completes Patient Enrollment In Two Phase 3 Studies Of Favipiravir For Influenza 2/17/2015
Navidea Biopharmaceuticals (NAVB) Release: Lymphoseek Results From Phase 3 Clinical Trial In Oral Cavity Cancer Of The Head And Neck Published In Annals Of Surgical Oncology 2/17/2015
Improved Survival In Children With Graft Versus Host Disease Who Respond To Mesoblast Limited (MSB.AX)'s Cell Therapy 2/16/2015
BIOCEO15: Gilead (GILD) COO Says 6-Week Timeline for Hep C Course Unrealistic, Outlines NASH, Cancer Strategies 2/12/2015
Eisai Inc. (ESALF.PK) Release: Pivotal Phase 3 Trial of Investigational Agent Lenvatinib In Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer Published In New England Journal Of Medicine 2/12/2015
Genzyme (GENZ) Presents Phase 3 Clinical Trial Extension Results For Cerdelga® (Eliglustat) At Lysosomal Disease Network’s WORLD Symposium 2015 2/12/2015
Chimerix (CMRX) Presents Update On Preliminary Data From Advise Study Of Brincidofovir For Adenovirus Infection At BMT Tandem Meetings 2/12/2015
The Philippines Is The 19th Country To Clear CEL-SCI (CVM) For Patient Enrollment In Its Phase III Head And Neck Cancer Trial 2/11/2015
Baxter International, Inc. (BAX) Presents Additional Data From Pivotal Study Of BAX 855, Extended Half-Life Investigational Recombinant FVIII Based On ADVATE For Hemophilia A 2/11/2015
Interim Phase 3 Results Positive for Takeda (TKPYY) Blood Cancer Med Ixazomib 2/10/2015
Anthera Pharmaceuticals, Inc. (ANTH) Announces Completion Of Interim Analysis From Phase 3 Trial With Blisibimod For Systemic Lupus Erythematosus 2/10/2015
Amicus Therapeutics, Inc. (FOLD) Announces Additional Positive Phase 3 Fabry Data On Patient Reported Outcomes At Worldsymposium 2015 2/10/2015
AB Science (AB.PA) : Successful Completion Of Futility Test For Masitinib In Alzheimer's Disease 2/10/2015
Galena Biopharma  (GALE) Enrolls 700th Patient In Neuvax (Nelipepimut-S) Phase 3 PRESENT Clinical Trial 2/9/2015
La Jolla Pharmaceutical Company (LJPC) Announces Special Protocol Assessment For Planned Phase 3 Trial Of LJPC-501 In Catecholamine-Resistant Hypotension 2/9/2015
Provectus Biopharmaceuticals Inc. Met With FDA On Operational Aspects Of PV-10 Phase 3 Melanoma Study 2/9/2015
Chiasma Inc. Release: Newly Published Phase 3 Study Results Show Positive Outcomes For Octreotide Capsules In People With Acromegaly, A Serious Hormonal Disorder 2/9/2015
GlaxoSmithKline (GSK) And Theravance, Inc. (THRX) Announce Start Of Phase 3 Lung Function Study With 'Closed' Triple Combination Treatment FF/UMEC/VI For COPD 2/9/2015
Newly Presented Data Shows That Peregrine Pharmaceuticals, Inc. (PPHM)' PS-Targeting Antibodies Significantly Enhance Anti-Tumor Activity Of Immune Checkpoint Inhibitors PD-1 And CTLA-4 In Models Of Breast Cancer And Melanoma 2/9/2015
Second Breakthrough Status Win for Genentech (RHHBY) Immunotherapy Drug 2/6/2015
GlaxoSmithKline (GSK) Touts Positive Data From Phase III COMBI-D Study 2/6/2015
Portola Pharmaceuticals, Inc.'s Factor Xa Inhibitor Betrixaban Successfully Passes Futility Analysis In Phase 3 APEX Study; Trial Continues As Planned And Remains On Track For Enrollment Completion By Year-End 2/6/2015
Cognoptix CEO Paul Hartung Says Company Is Preparing For A Pivotal Phase 3 Clinical Trial Of SAPPHIRE Eye Scan Being Developed To Aid In The Early Detection Of Alzheimer’s Disease 2/5/2015
Genentech (RHHBY) Shows Off Positive Phase III Lymphoma Data From Late-Stage Study 2/5/2015
Amgen (AMGN) Announces Positive Top-Line Results From Phase 3 Study Evaluating The Efficacy And Safety Of Biosimilar Candidate Abp 501 Compared With Adalimumab In Patients With Moderate-To-Severe Rheumatoid Arthritis 2/4/2015
Daiichi Sankyo, Inc. (4568.t) Announces First Patients In Large-Scale, Multi-National Phase 3 Clinical Programs For Mirogabalin 2/4/2015
Can-Fite BioPharma (CFBI) Completes Phase 2/3 Trial For CF101 In Treatment of Psoriasis 2/4/2015
Roche (RHHBY)’s Phase 3 Study Of Gazyva/Gazyvaro Showed Significant Benefit In Refractory Indolent Non-Hodgkin’s Lymphoma 2/4/2015
Genentech (RHHBY)’s Phase III Study Of Gazyva Showed Significant Benefit In Refractory Indolent Non-Hodgkin’s Lymphoma 2/4/2015
EXCLUSIVE: Esperion Therapeutics, Inc. (ESPR) CEO Says FDA Lift Means ETC-1002 Will Be in Phase III Trials By End of 2015 2/4/2015
Flexion Therapeutics (FLXN) Initiates Phase 3 Clinical Trial Of FX006 In Patients With Osteoarthritis Of The Knee 2/3/2015
CTI BioPharma Announces Independent DMC Recommendation To Continue GOG-0212 Phase 3 Study Of OPAXIO™ As Maintenance Therapy In Ovarian Cancer, An NRG Oncology/GOG Study 2/3/2015
Onconova Therapeutics Inc. (ONTX) Announces Clinical Development Plan For Rigosertib In Higher Risk Myelodysplastic Syndrome (HR-MDS) Patients After Failure Of Treatment With Hypomethylating Agents (Hmas) 2/3/2015
Ipsen (IPN.PA) Announces Topline Results Of Two Double-Blind Phase 3 Studies Of Dysport® In Lower Limb Spasticity In Children And In Adults 2/3/2015
FDA Grants Breakthrough Therapy Designation For Genentech (RHHBY)’s Investigational Cancer Immunotherapy MPDL3280A (Anti-PDL1) In Non-Small Cell Lung Cancer 2/2/2015
AbbVie (ABBV) Announces Top-Line Results From Phase 3 Study Of All-Oral Treatment For Hepatitis C In Japan 2/2/2015
Evoke Pharma, Inc. Outlines Progress On Clinical Program 2/2/2015
Chimerix, Inc. (CMRX) Focusing Efforts On CMV And Adenovirus Pivotal Trials 2/2/2015
Emmaus Life Sciences Phase 3 Sickle Cell Disease Trial Data Included In 2015 Highlights Of American Society of Hematology Program 2/2/2015
CEL-SCI (CVM) Reports Record Monthly Patient Enrollment In Its Phase III Head And Neck Cancer Trial 2/2/2015
Enanta Pharmaceuticals, Inc. Announces 95 Percent SVR12 Rate In Abbvie’s Phase 3 Study Of All-Oral Treatment For Hepatitis C Virus In Japanese Patients 2/2/2015



//-->